| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRCA | Common Stock | Award | $0 | +100K | +636.38% | $0.00 | 116K | Jul 21, 2023 | Direct | F1 |
| transaction | VRCA | Common Stock | Sale | -$163K | -33.8K | -29.2% | $4.83 | 81.9K | Jul 24, 2023 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2019 and 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shall vest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date. |
| F2 | Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |